# Comparison of Outcomes in Different Parkinson's Disease Subtypes

in the AAN Axon Registry®

Iris Chin, PhD1, Sarah Kranick, MD1, Heather E. Moss, MD, PhD1, Kathryn Sands1, Peng Jin, PhD1, Jeremy Peavey1, Craig Pfeifer, PhD1, Youssef Zarrouk1, Zhongdi Chu, PhD1, Michael Mbagwu, MD1, and Aracelis Z. Torres, PhD, MPH1

Verana Health, San Francisco, California, US, 2 Departments of Ophthalmology, Neurology & Neurological Sciences, Stanford University, Palo Alto, CA US

### **Objective**

To compare outcomes between Parkinson's Disease (PD) subtypes using measures extracted from clinical notes from the American Academy of Neurology (AAN) Axon Registry®, a neurology-specific patient registry of real-world de-identified electronic health record data.

### **Background**

- Akinetic-rigid (AR) and tremor-dominant (TD) subtypes have been identified in PD, with the latter demonstrating a milder progression. 1, 2
- Past studies have commonly leveraged scores on the Unified Parkinson's Disease Rating Scale (UPDRS) to classify patients into these subtypes.3,4
- · However, the UPDRS is not commonly administered at every neurology visit, Demonstrating that real-world data (RWD) can be leveraged to identify subtypes, and therefore distinctions in disease progression, will enable studies aimed at understanding differences in pharmaceutical targets of the subtypes.

## Design/Methods

At the time of the study (February 2023), there were 41 million patient visits from more than 2.6 million patients across more than 1,000 registered providers and 150 practices in the Axon Registry. To curate disease-specific data modules (Qdata®), Verana Health leverages VeraQ®, its clinician-directed and Al-enhanced population health data engine. Through the Qdata Parkinson's Disease module. over 15,000 PD patients were identified.

#### Classifying Patients into PD Subtypes

Patients' severity of tremor, bradykinesia, and rigidity scores at the earliest encounter within one year of their first PD ICD code were leveraged to classify patients into AR and TD subtypes.

- Severity of tremor, bradykinesia, and rigidity scores were curated from patients' clinical notes using fine-tuned deep-learning models, where at each encounter, patients' severity for each individual sign was classified into a score ranging from 0 (none) to 3 (severe).
- . A severity ratio was then calculated using the following formula: Tremor Score / Mean of Bradykinesia and Rigidity Scores
- Patients were classified as TD for ratios >= 1 and AR for ratios <0.8 (adopting Kang et al., 2005 methodology), All remaining patients were classified as Other.

#### Comparing Outcomes of PD Subtypes

- Subtypes were compared by presence and time to first presence on outcome measures of interest using chi-square and Mann-Whitney U tests, respectively.
- · Outcome measures of interest include postural instability, motor fluctuations, dyskinesia, and deep brain stimulation (DBS).
  - DBS was curated from linked claims data. All other measures were curated from clinical notes using deep-learning and/or rule-based approaches.

All variables curated from clinical notes were developed and assessed with notes labeled by a clinical expert. All algorithms achieved weighted model F1-scores >= 0.8 when evaluated against held-out test sets (n cases >= 150).

#### Results

#### Distribution of PD Subtypes

There were 3.641 PD patients who had entries for tremor. bradykinesia, and rigidity on the same encounter, within one year of their first PD ICD code, Of these patients, the largest proportion (48%) was classified into the AR subtype.


Demographic information is presented below for the AR, TD, and Other groups. The remaining analyses do not include the Other subgroup.

#### Age and Sex of PD Subtypes

	AR (n = 1764)	TD (n = 693)	Other (n = 1184)
Mean (SD) age at first PD ICD code	71.50 (9.42)	70.73 (9.47)	71.34 (9.28)
Mean (SD) age at severity encounter	71.63 (9.42)	70.86 (9.48)	71.48 (9.29)
N (%) males	1044 (59.18%)	430 (62.05%)	709 (59.88%)

#### Comparing Outcome Measures of PD Subtypes

. The AR subtype had a higher proportion of patients with postural instability (61% vs. 53%) and dyskinesia (11% vs. 7%), p-values <



### Results (cont.)

- The AR subtype had a shorter time to first encounter with postural instability, dyskinesia, and motor fluctuations, p-values < .05.
- No differences in DBS were found between subtypes.

Median (IQR) Months to First Encounter with Outcome Measure

	AR	TD	P
Postural Instability	0 (0 - 1.06)	0 (0 - 4.71)	< 0.01
Motor Fluctuations	3.87 ( 0 - 16.06)	6.35 (0 - 19.52)	0.03
Dyskinesia	7.23 (0 - 27.16)	25.06 (3.94 - 39.81)	0.02
DBS	6.26 (0.13 - 27.87)	8.19 (1.06 - 28.35)	0.63

### **Conclusions**

Using RWD, we successfully identified AR and TD subtypes and differences in progression profiles with the TD subtype showing milder progression patterns consistent with the previous literature. Differences in dyskinesia were particularly notable. Not only was there a higher proportion of patients with dyskinesia among the AR subtype, but the median time to first dyskinesia encounter was about 18 months earlier compared to the TD subtype. These findings demonstrate that RWD can be leveraged for subtype studies and outcome differences within PD

Reinoso, G., Allen, J. C., Jr., Au, W. L., Seah, S. H., Tay, K. Y., & Tan, L. C. (2015). Clinical evolution of Parkinson's disease and prognostic factors affecting

2 Ren, J., Hua, P., Li, Y., Pan, C., Yan, L., Yu, C., Zhang, L., Xu, P., Zhang, M., & Liu, W. (2020). Comparison of three motor subtype patients. Frontiers in Neurology, 11, 601225.

Parkinson's Disease Ratine Scale IMDS-UPDRS: Scale presentation and clinimetric testine results. Mov Disord. 2315; 2129-2170. \*Kene, G. A. Bronstein, J. M. Masterman, D. L. Redelines, M. Crum, J. A. & Ritz, B. (2005). Clinical characteristics in early Parkinson's

\*Baca, C. M., Benish, S., Videnovic, A., Lundgren, K., Magliocco, B., Schlerman, B., Palmer, L., & Jones, L. K., Jr. (2019). Axon Registry<sup>16</sup> data validation: Acc extraction and measure specification. Neurology (2018), 847–858.

#### **Funding and Disclaimers**

This study was funded by Verana Health and all authors are employees or consultants of Verana Health.

The Axon Registry's is an initiative of the American Academy of Neurology ("AAN"). There are limitations of the Axon Registry data.

The views expressed in this abstract represent those of the authors and do not necessarily represent the official views of the AAN.

